Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Jun;41(6):1313–1318. doi: 10.1128/aac.41.6.1313

In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.

M Tanaka 1, R V Srinivas 1, T Ueno 1, M F Kavlick 1, F K Hui 1, A Fridland 1, J S Driscoll 1, H Mitsuya 1
PMCID: PMC163906  PMID: 9174190

Abstract

2'-beta-Fluoro-2',3'-dideoxyadenosine (F-ddA) is an acid-stable purine dideoxynucleoside analog active against a wide spectrum of human immunodeficiency virus type 1 (HIV-1) and HIV-2 strains in vitro. F-ddA is presently undergoing a phase I clinical trial at the National Cancer Institute. We induced HIV-1 variants resistant to F-ddA by exposing wild-type HIV-1 (HIV-1LAI) to increasing concentrations of F-ddA in vitro. After 18 passages, the virus was fourfold less sensitive to F-ddA than HIV-1LAI. Sequence analyses of the passage 18 virus revealed changes in three amino acids in the reverse transcriptase (RT)-encoding region of the pol gene: P to S at codon 119 (P119S; present in 3 of 13 and 28 of 28 molecular clones before and after F-ddA exposure, respectively), V179D (0 of 13 and 9 of 28, respectively), and L214F (9 of 13 and 28 of 28, respectively). Drug sensitivity assays using recombinant infectious clones confirmed that P119S was directly responsible for the reduced sensitivity of HIV-1 to F-ddA. Various infectious clones with single or multiple amino acid substitutions conferring viral resistance against nucleoside RT inhibitors, including HIV-1 variants with multi-dideoxynucleoside resistance, were generally sensitive to F-ddA. The moderate level of resistance of HIV-1 to F-ddA, together with the lack of conferment of significant cross-resistance by the F-ddA-associated amino acid substitutions, warrants further investigation of F-ddA as a potential antiviral agent for use in treatment of HIV-1 infection.

Full Text

The Full Text of this article is available as a PDF (153.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Eron J. J., Chow Y. K., Caliendo A. M., Videler J., Devore K. M., Cooley T. P., Liebman H. A., Kaplan J. C., Hirsch M. S., D'Aquila R. T. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother. 1993 Jul;37(7):1480–1487. doi: 10.1128/aac.37.7.1480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fitzgibbon J. E., Howell R. M., Haberzettl C. A., Sperber S. J., Gocke D. J., Dubin D. T. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother. 1992 Jan;36(1):153–157. doi: 10.1128/aac.36.1.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gao Q., Gu Z. X., Parniak M. A., Li X. G., Wainberg M. A. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J Virol. 1992 Jan;66(1):12–19. doi: 10.1128/jvi.66.1.12-19.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Gao Q., Gu Z., Parniak M. A., Cameron J., Cammack N., Boucher C., Wainberg M. A. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1993 Jun;37(6):1390–1392. doi: 10.1128/aac.37.6.1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gao W. Y., Agbaria R., Driscoll J. S., Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 1994 Apr 29;269(17):12633–12638. [PubMed] [Google Scholar]
  6. Gao W. Y., Shirasaka T., Johns D. G., Broder S., Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 1993 May;91(5):2326–2333. doi: 10.1172/JCI116463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gong Y. F., Marshall D. R., Srinivas R. V., Fridland A. Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrob Agents Chemother. 1994 Jul;38(7):1683–1687. doi: 10.1128/aac.38.7.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gu Z., Gao Q., Fang H., Salomon H., Parniak M. A., Goldberg E., Cameron J., Wainberg M. A. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother. 1994 Feb;38(2):275–281. doi: 10.1128/aac.38.2.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Husson R. N., Shirasaka T., Butler K. M., Pizzo P. A., Mitsuya H. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. J Pediatr. 1993 Jul;123(1):9–16. doi: 10.1016/s0022-3476(05)81530-6. [DOI] [PubMed] [Google Scholar]
  10. Iversen A. K., Shafer R. W., Wehrly K., Winters M. A., Mullins J. I., Chesebro B., Merigan T. C. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol. 1996 Feb;70(2):1086–1090. doi: 10.1128/jvi.70.2.1086-1090.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kavlick M. F., Shirasaka T., Kojima E., Pluda J. M., Hui F., Jr, Yarchoan R., Mitsuya H. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine. Antiviral Res. 1995 Oct;28(2):133–146. doi: 10.1016/0166-3542(95)00044-m. [DOI] [PubMed] [Google Scholar]
  12. Kohlstaedt L. A., Wang J., Friedman J. M., Rice P. A., Steitz T. A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992 Jun 26;256(5065):1783–1790. doi: 10.1126/science.1377403. [DOI] [PubMed] [Google Scholar]
  13. Kozal M. J., Shafer R. W., Winters M. A., Katzenstein D. A., Merigan T. C. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis. 1993 Mar;167(3):526–532. doi: 10.1093/infdis/167.3.526. [DOI] [PubMed] [Google Scholar]
  14. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  15. Larder B. A., Kellam P., Kemp S. D. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature. 1993 Sep 30;365(6445):451–453. doi: 10.1038/365451a0. [DOI] [PubMed] [Google Scholar]
  16. Mahalingam M., Pozniak A., McManus T. J., Vergani D., Peakman M. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes. Clin Exp Immunol. 1995 Dec;102(3):481–486. doi: 10.1111/j.1365-2249.1995.tb03841.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Marquez V. E., Tseng C. K., Kelley J. A., Mitsuya H., Broder S., Roth J. S., Driscoll J. S. 2',3'-Dideoxy-2'-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem Pharmacol. 1987 Sep 1;36(17):2719–2722. doi: 10.1016/0006-2952(87)90254-1. [DOI] [PubMed] [Google Scholar]
  18. Marquez V. E., Tseng C. K., Mitsuya H., Aoki S., Kelley J. A., Ford H., Jr, Roth J. S., Broder S., Johns D. G., Driscoll J. S. Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV. J Med Chem. 1990 Mar;33(3):978–985. doi: 10.1021/jm00165a015. [DOI] [PubMed] [Google Scholar]
  19. Montaner J. S., Singer J., Schechter M. T., Raboud J. M., Tsoukas C., O'Shaughnessy M., Ruedy J., Nagai K., Salomon H., Spira B. Clinical correlates of in vitro HIV-1 resistance ot zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS. 1993 Feb;7(2):189–196. doi: 10.1097/00002030-199302000-00006. [DOI] [PubMed] [Google Scholar]
  20. Nunberg J. H., Schleif W. A., Boots E. J., O'Brien J. A., Quintero J. C., Hoffman J. M., Emini E. A., Goldman M. E. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J Virol. 1991 Sep;65(9):4887–4892. doi: 10.1128/jvi.65.9.4887-4892.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Reichman R. C., Tejani N., Lambert J. L., Strussenberg J., Bonnez W., Blumberg B., Epstein L., Dolin R. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI. Antiviral Res. 1993 Apr;20(4):267–277. doi: 10.1016/0166-3542(93)90071-p. [DOI] [PubMed] [Google Scholar]
  22. Rizza P., Santini S. M., Logozzi M. A., Lapenta C., Sestili P., Gherardi G., Lande R., Spada M., Parlato S., Belardelli F. T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells. J Virol. 1996 Nov;70(11):7958–7964. doi: 10.1128/jvi.70.11.7958-7964.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Ruxrungtham K., Boone E., Ford H., Jr, Driscoll J. S., Davey R. T., Jr, Lane H. C. Potent activity of 2'-beta-fluoro-2',3'-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice. Antimicrob Agents Chemother. 1996 Oct;40(10):2369–2374. doi: 10.1128/aac.40.10.2369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schinazi R. F., Lloyd R. M., Jr, Nguyen M. H., Cannon D. L., McMillan A., Ilksoy N., Chu C. K., Liotta D. C., Bazmi H. Z., Mellors J. W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993 Apr;37(4):875–881. doi: 10.1128/aac.37.4.875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Shafer R. W., Kozal M. J., Winters M. A., Iversen A. K., Katzenstein D. A., Ragni M. V., Meyer W. A., 3rd, Gupta P., Rasheed S., Coombs R. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J Infect Dis. 1994 Apr;169(4):722–729. doi: 10.1093/infdis/169.4.722. [DOI] [PubMed] [Google Scholar]
  26. Shirasaka T., Chokekijchai S., Yamada A., Gosselin G., Imbach J. L., Mitsuya H. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother. 1995 Nov;39(11):2555–2559. doi: 10.1128/aac.39.11.2555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Shirasaka T., Kavlick M. F., Ueno T., Gao W. Y., Kojima E., Alcaide M. L., Chokekijchai S., Roy B. M., Arnold E., Yarchoan R. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A. 1995 Mar 14;92(6):2398–2402. doi: 10.1073/pnas.92.6.2398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Shirasaka T., Yarchoan R., O'Brien M. C., Husson R. N., Anderson B. D., Kojima E., Shimada T., Broder S., Mitsuya H. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):562–566. doi: 10.1073/pnas.90.2.562. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. St Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 1991 Sep 27;253(5027):1557–1559. doi: 10.1126/science.1716788. [DOI] [PubMed] [Google Scholar]
  30. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Tudor-Williams G., St Clair M. H., McKinney R. E., Maha M., Walter E., Santacroce S., Mintz M., O'Donnell K., Rudoll T., Vavro C. L. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet. 1992 Jan 4;339(8784):15–19. doi: 10.1016/0140-6736(92)90140-x. [DOI] [PubMed] [Google Scholar]
  32. Ueno T., Shirasaka T., Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2',3'-dideoxynucleoside 5'-triphosphates. J Biol Chem. 1995 Oct 6;270(40):23605–23611. doi: 10.1074/jbc.270.40.23605. [DOI] [PubMed] [Google Scholar]
  33. Zhang D., Caliendo A. M., Eron J. J., DeVore K. M., Kaplan J. C., Hirsch M. S., D'Aquila R. T. Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 1994 Feb;38(2):282–287. doi: 10.1128/aac.38.2.282. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES